ZA200001851B - Stable crystalline salts of 5-methyltetrahydrofolic acid. - Google Patents

Stable crystalline salts of 5-methyltetrahydrofolic acid.

Info

Publication number
ZA200001851B
ZA200001851B ZA200001851A ZA200001851A ZA200001851B ZA 200001851 B ZA200001851 B ZA 200001851B ZA 200001851 A ZA200001851 A ZA 200001851A ZA 200001851 A ZA200001851 A ZA 200001851A ZA 200001851 B ZA200001851 B ZA 200001851B
Authority
ZA
South Africa
Prior art keywords
crystalline salts
stable crystalline
methyltetrahydrofolic acid
methyl
tetrahydrofolic acid
Prior art date
Application number
ZA200001851A
Other languages
English (en)
Inventor
Hans Rudolf Mueller
Rudolf Moser
Thomas Egger
Original Assignee
Eprova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4193016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200001851(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eprova Ag filed Critical Eprova Ag
Publication of ZA200001851B publication Critical patent/ZA200001851B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200001851A 1999-04-15 2000-04-12 Stable crystalline salts of 5-methyltetrahydrofolic acid. ZA200001851B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH00695/99A CH693905A5 (de) 1999-04-15 1999-04-15 Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.

Publications (1)

Publication Number Publication Date
ZA200001851B true ZA200001851B (en) 2000-12-06

Family

ID=4193016

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200001851A ZA200001851B (en) 1999-04-15 2000-04-12 Stable crystalline salts of 5-methyltetrahydrofolic acid.

Country Status (19)

Country Link
US (1) US6441168B1 (hu)
EP (5) EP2192120B1 (hu)
JP (4) JP5202774B2 (hu)
KR (2) KR100774012B1 (hu)
CN (1) CN1154648C (hu)
AT (2) ATE451372T1 (hu)
AU (1) AU782641B2 (hu)
CA (1) CA2305926C (hu)
CH (1) CH693905A5 (hu)
CY (2) CY1109874T1 (hu)
DE (2) DE50015815D1 (hu)
DK (4) DK1044975T3 (hu)
ES (3) ES2374371T3 (hu)
HU (1) HU229423B1 (hu)
NO (1) NO325495B1 (hu)
PT (4) PT1044975E (hu)
RU (1) RU2265605C2 (hu)
TW (1) TWI285205B (hu)
ZA (1) ZA200001851B (hu)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US20020094970A1 (en) * 2000-12-14 2002-07-18 Ronenn Roubenoff Compositions and methods for treating an arthritic condition
DK1708690T3 (en) 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
KR20060051135A (ko) * 2004-09-15 2006-05-19 니프로 가부시키가이샤 안정화된 주사용 수용액 제재
AU2005313940A1 (en) * 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US8617597B2 (en) * 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
DE112007001600A5 (de) * 2006-07-06 2009-04-30 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
EP2027855A1 (de) 2007-08-24 2009-02-25 Bayer Schering Pharma AG Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität
US20090060997A1 (en) * 2007-08-27 2009-03-05 Christian Seitz Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and (6s)-5-methyltetrahydrofolate
EP2252261A2 (en) * 2008-02-13 2010-11-24 Bayer Schering Pharma Aktiengesellschaft Drug delivery system with stabilising effect
CA2714340A1 (en) * 2008-02-13 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
HUE025450T2 (hu) * 2008-02-20 2016-04-28 Gnosis Spa Folátok, azokat tartalmazó készítmények és alkalmazásuk
AU2010271178B2 (en) 2009-07-10 2015-10-22 Linzy O. Scott Iii Methods and compositions for treating thyroid-related medical conditions with reduced folates
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
EP3949973A3 (en) 2010-02-12 2022-07-06 Gentelon, Inc. Compositions and methods for treating depression
JP5785622B2 (ja) * 2010-12-03 2015-09-30 コチャク ファルマ イラチュ ヴェキミャ サン．アー．シェーＫｏｃａｋ Ｆａｒｍａ Ｉｌａｃ Ｖｅ Ｋｉｍｙａ Ｓａｎ．Ａ．Ｓ その構造内にグルタミン酸部分を有する葉酸拮抗薬の新規な製造方法
CN102516247A (zh) * 2010-12-15 2012-06-27 连云港金康医药科技有限公司 A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法
EP2502625A1 (en) 2011-03-21 2012-09-26 GMT Fine Chemicals SA Process for the preparation of crystalline levofolinic acid
CN102775407B (zh) * 2012-01-20 2015-08-05 连云港金康医药科技有限公司 稳定的无定型5-甲基四氢叶酸盐及其制备方法
CN102702200B (zh) * 2012-04-25 2014-11-12 连云港金康和信药业有限公司 (6rs)-5-甲基四氢叶酸钙盐晶型及其制备方法
CN102584826B (zh) * 2012-01-20 2015-04-29 连云港金康医药科技有限公司 (6s)-5-甲基四氢叶酸盐晶型及其制备方法
KR101694710B1 (ko) * 2012-01-20 2017-01-10 리안윤강 진강 해신 파머수티컬 코. 엘티디. (6s)-5-메틸 테트라히드로 엽산염 결정형 및 그 제조방법
WO2013163917A1 (zh) * 2012-04-13 2013-11-07 连云港金康和信药业有限公司 化合物jk12a及其制备
CN103450202B (zh) * 2012-06-04 2015-07-01 南京莱因医药科技有限公司 L-5-甲基四氢叶酸与有机碱加成盐的方法
CN103664945B (zh) * 2012-09-07 2016-01-20 南京莱因医药科技有限公司 L-5-甲基四氢叶酸氨基酸盐的制备方法
CN103694239B (zh) * 2012-09-27 2016-12-21 上海科胜药物研发有限公司 一种5‑甲基‑（6s）‑四氢叶酸晶型a及其制备方法
EP2781214A1 (en) * 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
JP2016525576A (ja) * 2013-07-29 2016-08-25 アデア ファーマシューティカルズ，インコーポレイテッド 安定化された修飾放出型葉酸誘導体組成物、その治療用途および製造方法
US20160053281A1 (en) 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
US9492421B1 (en) 2013-11-14 2016-11-15 Argent Development Group, Llc Nutritional supplements for treatment of iron deficiency anemia
US9629846B1 (en) 2013-11-14 2017-04-25 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
EP2878600B1 (en) 2013-12-02 2018-06-27 Cerbios-Pharma S.A. Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol
CN103980279B (zh) * 2014-04-16 2016-07-06 悦康药业集团有限公司 一种甲氨蝶呤化合物及注射用甲氨蝶呤
WO2015193778A1 (en) 2014-06-16 2015-12-23 Mylan Laboratories Ltd. Crystalline form of levomefolate calcium
CN104490887A (zh) * 2014-09-04 2015-04-08 连云港金康和信药业有限公司 (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物
KR20170047394A (ko) 2014-09-04 2017-05-04 리안윤강 진강 해신 파머수티컬 코. 엘티디. (6s)-5-메틸테트라히드로폴산 또는 그 염의 조성물 및 그 제조와 용도
CN104225609B (zh) 2014-09-20 2018-05-18 中国药科大学 一种炎症靶向的中性粒细胞递药系统及其应用
WO2016135707A1 (en) 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
WO2016185413A1 (en) 2015-05-20 2016-11-24 Nestec S.A. Modified release formulations
CN107698591A (zh) * 2015-09-25 2018-02-16 上海华理生物医药有限公司 (6s)-5-甲基四氢叶酸锌盐晶型及其制备方法
DE202015105351U1 (de) 2015-10-09 2016-01-07 Apotheke am Schlossplatz Inh. Mario Ganster e.K. Diätetische Zusammensetzung
KR101712807B1 (ko) 2015-10-19 2017-03-07 오인숙 스테인레스 빔 제조장치
CN105237539A (zh) * 2015-10-29 2016-01-13 上海应用技术学院 A晶型(6s)-5-甲基四氢叶酸锌盐及其制备方法
CN107304212A (zh) * 2016-04-21 2017-10-31 常州爱诺新睿医药技术有限公司 一种无定型l-5-甲基四氢叶酸氨基酸盐及其制备方法
AU2017397463B2 (en) 2016-11-03 2022-01-06 HedoniaUSA, Inc. Compositions and methods for treating depression
WO2018178144A1 (en) 2017-03-31 2018-10-04 Merck Patent Gmbh Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid
JP7285785B2 (ja) * 2017-03-31 2023-06-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ５－メチル－（６ｓ）－テトラヒドロ葉酸の結晶性ナトリウム塩
CA3058289A1 (en) 2017-03-31 2018-10-04 Merck Patent Gmbh Crystalline binary sodium salts of 5-methyl-(6s)-tetrahydrofolic acid with organic bases
EP3461826A1 (en) 2017-09-29 2019-04-03 Aprofol AG Multifunctional folate salts
WO2020007843A1 (en) 2018-07-06 2020-01-09 Merck Patent Gmbh Crystalline salts of 5-methyl-(6s)-tetrahydrofolic acid and amino acid ethyl esters
PL3818048T3 (pl) * 2018-07-06 2024-03-18 Merck Patent Gmbh Krystaliczna sól zawierająca kwas 5-metylo-(6s)-tetrahydrofoliowy i 4-(2-hydroksyetylo)-morfolinę
US11992491B2 (en) 2018-07-06 2024-05-28 Merck Patent Gmbh Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester
DK3817812T3 (da) * 2018-07-06 2023-11-27 Merck Patent Gmbh Krystallinsk salt af 5-methyl-(6s)-tetrahydrofolsyre og l-isoleucinethylester
ES2966940T3 (es) 2018-07-06 2024-04-25 Merck Patent Gmbh Sales cristalinas de ácido 5-metil-(6S)-tetrahidrofólico y éster etílico de L-leucina
EP3646873A1 (en) * 2018-10-31 2020-05-06 Aprofol AG Folate salts
EP3666260A1 (en) 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof
US20230162351A1 (en) 2020-04-23 2023-05-25 National University Corporation Shiga University Of Medical Science Diagnosis assistance device, machine learning device, diagnosis assistance method, machine learning method, machine learning program, and alzheimers prediction program
US20230181475A1 (en) 2020-05-15 2023-06-15 Alfasigma S.P.A. Composition comprising methylfolate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223500A (en) * 1977-02-22 1993-06-29 Bioresearch S.P.A. Stable pharmaceutical composition of alkaline or alkaline earth 5-methyl tetrahydrofolate
GB1572137A (en) 1977-02-22 1980-07-23 Bioresearch Sas Del Dr Livio C Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts
DE3821875C1 (hu) 1988-06-29 1990-02-15 Eprova Ag, Forschungsinstitut, Schaffhausen, Ch
CH680731A5 (hu) * 1990-04-12 1992-10-30 Sapec Fine Chemicals
CH681303A5 (hu) 1991-01-16 1993-02-26 Eprova Ag
CH684270A5 (de) 1991-10-04 1994-08-15 Sapec Fine Chemicals Verfahren zur Herstellung von Erdalkalimetallsalzen von (6R)-N(10)-Formyl-5,6,7,8-tetrahydrofolsäure.
CH683261A5 (it) * 1991-10-10 1994-02-15 Applied Pharma Res Procedimento per la preparazione dell'acido metiltetraidrofolico nella forma (6(R,S)(-))N-5 e separazione del diastereoisomero attivo (6(S)(-))N-5) sotto forma di sali.
CH682664A5 (en) 1991-10-15 1993-10-29 Eprova Ag Stable salts of 5,10-methylene tetrahydrofolate.
CH682665A5 (de) 1991-10-29 1993-10-29 Sapec Fine Chemicals Verfahren zur Reinigung von rohen Erdalkalimetallsalzen von N(5)-Methyl-5,6,7,8-tetrahydrofolsäure.
DE4136921A1 (de) * 1991-11-11 1993-05-13 Knoll Ag Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure
CH686672A5 (de) * 1992-12-01 1996-05-31 Cerbios Pharma Sa Verfahren zur Herstellung von (6S)-5,6,7,8-Tetrahydrofolsaeure.
CH686369A5 (de) * 1994-05-09 1996-03-15 Eprova Ag Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure.
CH689831A5 (de) 1995-11-07 1999-12-15 Eprova Ag Stabile kristalline Tetrahydrofolsaeure-Salze.
DE69728379T2 (de) 1996-01-31 2005-02-24 South Alabama Medical Science Foundation, Mobile Lebensmittel und vitamin herstellungen mit natürlichem isomeren von reduzierten folaten
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.

Also Published As

Publication number Publication date
JP2013047280A (ja) 2013-03-07
PT2194057E (pt) 2012-01-16
CY1109874T1 (el) 2014-09-10
DE50016064D1 (de) 2011-03-03
JP5675760B2 (ja) 2015-02-25
EP2192120B1 (de) 2011-10-26
DK2189459T3 (da) 2011-04-18
ES2336190T3 (es) 2010-04-09
DK1044975T3 (da) 2010-03-22
NO20001886L (no) 2000-10-16
KR20070062964A (ko) 2007-06-18
TWI285205B (en) 2007-08-11
HUP0001560A3 (en) 2003-04-28
JP5675759B2 (ja) 2015-02-25
HU229423B1 (en) 2013-12-30
AU782641B2 (en) 2005-08-18
JP2013047278A (ja) 2013-03-07
DK2194057T3 (da) 2012-01-16
KR100874368B1 (ko) 2008-12-16
KR100774012B1 (ko) 2007-11-08
JP2013047279A (ja) 2013-03-07
NO20001886D0 (no) 2000-04-12
EP1044975B1 (de) 2009-12-09
CA2305926A1 (en) 2000-10-15
EP2194057A1 (de) 2010-06-09
EP2192120A1 (de) 2010-06-02
HU0001560D0 (en) 2000-06-28
NO325495B1 (no) 2008-05-19
JP5675758B2 (ja) 2015-02-25
DK2192120T3 (da) 2012-01-16
HUP0001560A2 (hu) 2001-04-28
AU2768900A (en) 2000-10-19
PT1044975E (pt) 2010-03-09
EP1695975A1 (de) 2006-08-30
CH693905A5 (de) 2004-04-15
DE50015815D1 (de) 2010-01-21
CA2305926C (en) 2008-10-07
KR20010014732A (ko) 2001-02-26
CY1111313T1 (el) 2015-08-05
ATE451372T1 (de) 2009-12-15
JP2000327680A (ja) 2000-11-28
ES2374369T3 (es) 2012-02-16
CN1277197A (zh) 2000-12-20
EP2189459B1 (de) 2011-01-19
US6441168B1 (en) 2002-08-27
EP2189459A1 (de) 2010-05-26
ES2374371T3 (es) 2012-02-16
PT2192120E (pt) 2012-01-16
JP5202774B2 (ja) 2013-06-05
CN1154648C (zh) 2004-06-23
PT2189459E (pt) 2011-04-14
EP1044975A1 (de) 2000-10-18
ATE496052T1 (de) 2011-02-15
EP2194057B1 (de) 2011-10-26
RU2265605C2 (ru) 2005-12-10

Similar Documents

Publication Publication Date Title
ZA200001851B (en) Stable crystalline salts of 5-methyltetrahydrofolic acid.
HUP0204034A3 (en) Stable salts of novel derivatives of 3,3-diphenylpropylamines
EP1277754B8 (en) Imidazopyridine derivatives
HUP0104199A3 (en) Substituted pyrimido pyrimidinone derivatives, pharmaceutical compositions containing the same, process for the preparation thereof and intermediates
ZA953673B (en) Stable crystalline (6S)- and (6R)- tetrahydrofolic acid
CA2384037A1 (en) Pyrazolo[4,3-d]pyrimidines
CA2187409A1 (en) Stable Crystalline Tetrahydrofolic Acid Salts
WO2002080914A3 (de) VERWENDUNG VON SUBSTITUIERTEN IMIDAZO[1,2-a]-PYRIDINVERBINDUNGEN ALS ARZNEIMITTEL
AU7492591A (en) Diastereoisomeric compounds derived from tetrahydrofolic acid, process for their preparation and use in the synthesis of diastereoisomers 6s and 6r of reduced folates
WO2001019826A3 (en) Triazolopyrimidine derivatives
ZA200305877B (en) Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof.
CA2423357A1 (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors
MXPA03009681A (es) METODO PARA TRATAMIENTO DE TUMORES POR ADMINISTRACIoN DE TEGAFUR, URACILO, ACIDO FOLINICO, Y CICLOFOSFAMIDA.
TW353070B (en) Chloropyridylcarbonyl derivatives
IL160162A0 (en) Salts of substituted 1,2,3,4,-tetrahydroisoquinolie-2-carboxylic acid derivatives
ATE530550T1 (de) Stabiles kristallines calcium-salz der 5-methyl- (6s)-tetrahydrofolsäure
CA2383373A1 (en) Synthesis of [3,5,7]-1h-imidazo[1,5-a]imidazol-2(3h)-one compounds
PL357568A1 (en) Novel pyrazine derivatives or salts thereof, pharmaceutical compositions containing the derivatives or the salts and intermediates for the preparation of both
MXPA03002497A (es) Procedimiento para la obtencion de derivados de acidos cetocarboxilicos.
HUP0002306A3 (en) Novel naphthyridine derivatives or salts thereof, process for their preparation, pharmaceutical compositions and use thereof
ZA200002375B (en) Process for preparing 2-phenyl-3-aminopyridine, substituted phenyl derivatives thereof, and salts thereof.
AU2001292498A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain